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Abstract
Since P450scc transforms 7-dehydrocholesterol (7DHC) to 7-dehydropregnenolone (7DHP) in vitro, we investigated sequential
7DHC metabolism by adrenal glands ex vivo. There was a rapid, time- and dose-dependent metabolism of 7DHC by adrenals
from rats, pigs, rabbits and dogs with production of more polar 5,7-dienes as detected by RP-HPLC. Based on retention time
(RT), UV spectra and mass spectrometry, we identified the major products common to all tested species as 7DHP, 22-hydroxy-
7DHC and 20,22-dihydroxy-7DHC. The involvement of P450scc in adrenal metabolic transformation was confirmed by the
inhibition of this process by DL-aminoglutethimide. The metabolism of 7DHC with subsequent production of 7DHP was
stimulated by forscolin indicating involvement of cAMP dependent pathways. Additional minor products of 7DHC metabolism
that were more polar than 7DHP were identified as 17-hydroxy-7DHP (in pig adrenals but not those of rats) and as pregna-4,7-
diene-3,20-dione (7-dehydroprogesterone). Both products represented the major identifiable products of 7DHP metabolism in
adrenal glands. Studies with purified enzymes show that StAR protein likely transports 7DHC to the inner mitochondrial
membrane, that 7DHC can compete effectively with cholesterol for the substrate binding site on P450scc and that the catalytic
efficiency of 3bHSD for 7DHP (Vm/Km) is 40% of that for pregnenolone. Skin mitochondria are capable of transforming 7DHC to
7DHP and the 7DHP is metabolized further by skin extracts. Finally, 7DHP, its photoderivative 20-oxopregnacalciferol, and
pregnenolone exhibited biological activity in skin cells including inhibition of proliferation of epidermal keratinocytes and
melanocytes, and melanoma cells. These findings define a novel steroidogenic pathway: 7DHCR22(OH)7DH-
CR20,22(OH)27DHCR7DHP, with potential further metabolism of 7DHP mediated by 3bHSD or CYP17, depending on
mammalian species. The 5–7 dienal intermediates of the pathway can be a source of biologically active vitamin D3 derivatives
after delivery to or production in the skin, an organ intermittently exposed to solar radiation.
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Introduction
For decades it has been assumed that in mammalian systems all
major steroidogenic pathways, including the chemical structures of
final products and intermediates, are well established. These
pathways start with cytochrome P450scc mediated production of
pregnenolone, a precursor to all steroids [1,2]. P450scc (product of
the CYP11A1 locus) is a mitochondrial enzyme that catalyzes two
successive hydroxylations of the cholesterol side chain at positions
22 and 20, followed by its cleavage to produce pregnenolone and
isocaproic aldehyde [3,4]. Electrons for the reactions are provided
by NADPH via adrenodoxin reductase and adrenodoxin [5,6].
P450scc is predominantly expressed in adrenals and gonads which
produce steroid hormones for systemic use, and is expressed at a
lower level in the placenta. Very low expression of P450scc
has also been detected in brain [7], kidney [8], gut [9], and skin
[10–12], indicating production of pregnenolone at these sites for
local use.
Most recently it has been uncovered that the same enzyme,
P450scc, cleaves the side chain of 7-dehydrocholesterol (7DHC), a
direct precursor to cholesterol to produce 7-dehydropregnenolone
(7DHP) [10,13]. The efficiency of this process is the same as for
cholesterol conversion to pregnenolone [10]. This suggests that
P450scc action on 7DHC can start a novel metabolic pathway for
production of steroids with an unsaturated B ring [10]. 7-DHC
contains an unsaturated B ring (two double bonds in position 5
and 7) that is reduced by delta-7 reductase to produce cholesterol
[14,15]. Defects in this enzyme leads to reduced or absent 7DHC
transformation to cholesterol with accumulation of steroidal 5,7-
dienes, well described in the Smith Lemli Opitz Syndrome (SLOS)
[16–18]. The latter suggests an in vivo action of P450scc on 7DHC,
at least under the pathological condition of SLOS.
PLoS ONE | www.plosone.org 1 February 2009 | Volume 4 | Issue 2 | e4309Figure 1. 7DHC metabolism by rat adrenal glands. Finely cut fragments of rat adrenal glands were incubated in the presence (B–D) or absence
(A) of 7DHC (0.5 mM). Boiled adrenal fragments (C) served as an additional negative control. Panel B shows results from an incubation which
included trilostane, a 3bHSD inhibitor. Steroids were extracted with methylene chloride and subjected to LC/MC and UV spectra analyses. Panels A–D
identifies 7 main products. Product 3 had an identical retention time to 7DHP standard. Panel E shows UV spectra, MS and the predicted structures of
the 7 metabolites.
doi:10.1371/journal.pone.0004309.g001
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PLoS ONE | www.plosone.org 2 February 2009 | Volume 4 | Issue 2 | e4309Skin is an example of an organ with a low steroidogenic
potential [10,19]. However, it accumulates significant amounts of
7DHC which is localized to the plasma membrane of basal
epidermal keratinocytes, where it undergoes photolysis of the B
ring upon absorption of photons of ultraviolet light B (wavelength
280–320 nm) to form previtamin D3, which then undergoes
internal rearrangement to form vitamin D3 [19–22]. Interestingly,
vitamin D3 as well as plant derived ergosterol or vitamin D2, are
also metabolized by P450scc without cleavage of the side chain in
reactions that generate mono-, di-, tri-hydroxy products
[12,13,23–25], some of which show biological activity in skin cells
cultured in vitro [12,23,26].
Thus, it has become crucial to test whether organs expressing
P450scc can generate 5,7-diene steroids and to define whether
they are biologically active. To test this hypothesis we have
incubated fragments of adrenal glands (an example of a tissue with
high P450scc activity) from different mammalian species with
7DHC and tested its metabolism to 7DHP and it derivatives. The
capability of skin extracts (example of a tissue with low P450scc
activity) to metabolize 7DHC and 7DHP was also tested. To
establish the relative biological activity of the intermediates of the
pathway we used skin cells to test the effects of products of P450scc
action on cholesterol and 7DHC, namely, pregnenolone and
7DHP, as well as the product of UV mediated photolysis of 7DHP,
20-oxopregnacalciferol (pD3).
Results and Discussion
1. Metabolism of 7DHC in the adrenal glands ex vivo
We incubated minced rat adrenal glands with (test) or without
7DHC (negative control) as described in the Materials and Methods.
A second negative control comprised boiled adrenal glands
incubated with 7DHC. The samples were extracted with methylene
chloride and analyzed on an LC–MS QP8000aequipped with diode
Figure 2. Precursor-product relationship between 7DHC, hydroxy-7DHC, dihydroxy-7DHC and 7DHP defined by their sequential
metabolism by rat adrenal glands. A. Chromatogram showing metabolism of 7DHC(S) by adrenal glands. The hydroxy-7DHC (1) and dihydroxy-
7DHC (2) products were collected from the HPLC and tested as substrates (see B–E). Product 3 was identified as 7-DHP based on RT, mass and UV
spectra. B. Incubation of hydroxy-7DHC (1) with adrenal glands generated dihydroxy-7DHC with RT 34.8 min (2) and 7DHP with RT 15.8 min (3). C.
Boiled adrenal glands served as a control for B. D. Incubation of dihydroxy-7DHC (2) with adrenal glands produced 7DHP; note the lack of S and
product 1. E. Negative control for D (boiled adrenal glands ). Inserts: UV spectra of compounds 1–3.
doi:10.1371/journal.pone.0004309.g002
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a representative experiment (Fig. 1) show that 7DHC is metabolized
by adrenal glands to four specific products represented by three
major peaks (peaks 1–3) and one minor peak (peak 5, Fig. 1D). Peaks
4, 6 and 7 correspond to products of endogenous cholesterol
metabolism as they are present in the control (Fig. 1A) and are
identified as progesterone, deoxycorticosterone and corticosterone,
based on their mass and UV spectra as well as their retention times
(RT) compared to authentic standards (Fig. 1 E). Using the same
identification criteria (Fig. 1 E), product 3 is identified as 7DHP, and
products 1 and 2 tentatively as 22-hydroxy-7DHC (22(OH)7DHC),
20,22-dihydroxy-7DHC (20,22(OH)27DHC), respectively. Product
5 is defined as 4,7-pregandien-3,20-dione (7-dehydroprogesterone),
which is consistent with m/z=313 for [M+1]
+ (real mass of 312),
UV lmax of 238, and its disappearance after incubation with
trilostate (T), an inhibitor of 3b-hydroxysteroid dehydrogenase
(3bHSD) (Fig. 1 B, E). To establish a precursor-product relationship
between compounds 1–3 we performed an additional experiment
where purified products 1 and 2 were individually incubated with rat
adrenal glands (Fig 2). This shows that there is sequential
transformation of product 1 to the more polar 5,7- diene (product
2)and7DHP,and thesoleconversionofproduct2to7DHP.Taking
into consideration that the initial hydroxylation of the cholesterol
side chain occurs at C22 [27] and given that 7DHC and cholesterol
metabolism by P450scc are very similar [10], we defined product 1
as 22(OH)7DHC and product 2 as (20,22(OH)27DHC).
Next we analyzed whether similar metabolism of 7DHC occurs in
other mammalian species. Briefly, minced adrenal glands from rats
(positive control), rabbits, dogs or pigs were incubated with or
without 0.5 mM 7DHC and processed as described above. In these
experiments the extracted samples were analyzed with a RP-HPLC
Waters dual pump chromatography system equipped with a
photodiode array. Figure 3 shows that adrenal glands from rabbits,
dogs and pigs metabolize 7DHC to three major 5,7-diene products
(UVlmax261,271,281,293),identifiedfromratsamplesas7DHP,
22(OH)7DHC and 20,22(OH)27DHC. These experiments also
showtheproductionofmorepolarcompounds,onewithRT21 min
(most likely 7-dehydroprogesterone as defined for compound with
RT of 26.2 min in experiment presented in Fig. 1E and another
which was a 5,7-diene with a short RT of 14.7 min seen in rabbit
and pig samples (Fig. 3). The identity of the 7DHP was determined
by its identical RT (22 min) with 7DHP synthetic standard. The
production of 7DHP was time- and dose- dependent and dependent
on the amount of tissue used. Separate LC/MS mass spectrometry
analyses of the pig adrenal samples were performed on a Bruker
Esquire-LC/MS Spectrometer equipped with an electrospray
ionization source (ESI) and showed the expected real masses for
monohydroxy-7DHC (1), dihydroxy-7DHC (2), 7DHP (3) and 17-
hydroxy-7DHP(4)(Fig.4).ThecollectedpeakshadtheexpectedUV
spectra for 5,7-dienes, and peaks 3 and 4 had identical retention
times to 7DHP and 17(OH)7DHP standards. We thus conclude that
mammalian adrenal glands metabolize 7DHC in the sequence
7DHCR22(OH)7DHCR20,22(OH)27DHCR7DHP, with poten-
tial further metabolism of the 7DHP by 3bHSD or CYP17, de-
pending on the mammalian species. The detection of 17(OH)7DHP
in pig adrenals but not in those of rats is consistent with expression of
CYP17 in the former but not latter species [28,29].
The sequential metabolism of 7DHC to 7DHP in rat and pig
adrenal glands, and to 17(OH)7DHP in pig, was inhibited by DL-
aminoglutethimide (AGT, an inhibitor of P450scc) and stimulated
by forscolin (Fig. 5A–C). The former demonstrates that this
metabolism is dependent on P450scc activity [30], while the latter
indicates positive regulation by cAMP, as it is in case of the
classical steroidogenic pathway that starts from the cholesterol
Figure 3. Metabolism of 7-DHC by adrenal glands of different mammalian species. Finely cut fragments of rat (A), rabbit (B), dog (C) and
pig (D) adrenals were incubated in the presence (blue) or absence (green) of 7DHC (S). Boiled adrenal fragments served as an additional negative
control for the rat (red). The three major products common to all animals studied are numbered 1 to 3 on the chromatograms. Product 3 had an
identical retention time, mass, and UV spectra to 7DHP standard.
doi:10.1371/journal.pone.0004309.g003
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PLoS ONE | www.plosone.org 4 February 2009 | Volume 4 | Issue 2 | e4309Figure 4. Metabolism of 7DHC by pig adrenal glands. Fragments of pig adrenal glands were incubated with 0.5 mM 7DHC. Steroids were
extracted with methylene chloride and subjected to HPLC and UV spectral analyses. The UV spectrum for all peaks is the same (see arrows). The mass
spectra of the collected peaks 1–4 were obtained by direct injection into the MS module of the Bruker Esquire-LC/MS Spectrometer.
doi:10.1371/journal.pone.0004309.g004
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enhanced by trilostane (an inhibitor of 3bHSD) and by AY-9944
and BM15.766 (inhibitors of D
7-reductase)(Fig. 5D,E). Thus the
inhibition of 3bHSD with resulting accumulation of steroidal 5,7-
diene intermediates (including hydroxy-7DHP) demonstrates that
7DHP enters the D
4 steroidogenic pathway. This is further
supported by detection of steroidal 4,7-dienes in SLOS patients
[32,33]. The increased accumulation of the 7DHC precursor and
steroidal 5,7- diene intermediates after inhibition of D
7-reductase
demonstrate that the unsaturated B ring of 7DHC (and potentially
of its metabolites) is reduced in the adrenal to generate cholesterol
and the expected steroids. However, the relative efficiency of this
catalytic reduction of the 7–8 double bond is very low as
demonstrated in Fig. 1.
To better define the later steps of the above metabolic pathway,
we used 7DHP as the substrate. Incubation of 7DHP with minced
adrenal glands resulted in time-dependent generation of more polar
products (Fig. 6A and 7A). Production of the compounds
corresponding to peaks with RT of 19.2 min (1) and 18 min (2)
was inhibited by trilostane (Figs. 6B and 7), while the amount of
product with RT of 14.7 min (3), present only in the pig, was
increased (Fig. 6B, C). Product 3 had UV lmax (261,270,281,
290 nm) and identical RT to 17(OH)7DHP. The LC/MS analysis
performed with pig adrenal gland samples further confirmed that
product 3 is indeed 17(OH)7DHP, and helped us assign products 1
and 2 as 7-dehydroprogesterone and progesterone, respectively
(Fig. 8 and cf. Figs. 1, 6 and 7). These results further strengthen our
proposal that in vivo sequential metabolism of 7DHC in adrenal
glands is initiated by P450scc, involves 3bHSD and, depending on
the species, CYP17 (Fig. 9). Importantly, this model provides
additional proof that several metabolites identified in tissues and
body fluids of SLOS patients [16,32,33] can indeed be of adrenal
origin.
2. Experiments with purified enzymes
To further define the ability of steroidogenic enzymes in the
adrenal cortex to metabolize 7DHC, additional studies were
carried out with purified enzymes (Fig. 10). Metabolism of 7DHC
by P450scc requires delivery of the 7DHC to the inner
mitochondrial membrane where the P450scc is located [2]. Since
cholesterol delivery to P450scc in the adrenal cortex and gonads is
rate limiting for steroid synthesis and is mediated by the StAR
protein [34], we tested the ability of recombinant N-62 StAR
protein to transport 7DHC between phospholipid membranes.
7DHC displayed a basal rate of exchange between the membranes
of phospholipid vesicles twice that for cholesterol. N-62 StAR
protein (5 mM) stimulated the rate of 7DHC transfer by at least 20
fold, with the initial rate being too rapid to measure accurately
(Fig. 10A). The rate of transfer of 7DHC by N-62 StAR protein
was comparable to rate of cholesterol transfer by this carrier. Thus
the StAR protein provides a likely carrier for transport of 7DHC
to the inner mitochondrial membrane of the adrenal cortex for its
metabolism by P450scc.
Once at the site of P450scc in the inner mitochondrial
membrane, 7DHC must compete with cholesterol to be
metabolized. Since both bovine and human enzymes display
similar kcat/Km values for 7DHC and cholesterol, close compe-
tition between these substrates would be expected [10]. To test this
we examined the ability of unlabelled 7DHC to compete with, and
thus inhibit, the conversion of [4-
14C]cholesterol to [4-
14C]preg-
nenolone by purified bovine P450scc incorporated into phospho-
lipid vesicles (Fig. 10B). 7DHC at a molar ratio to phospholipid of
0.2 proved to be a competitive inhibitor of the side chain cleavage
of cholesterol, increasing the Km 3-fold without affecting Vmax.
The calculated KI for 7DHC (0.1 mol 7DHC/mol phospholipid
was lower than the Km for cholesterol (0.14 mol /mol phospho-
lipid), therefore 7DHC can compete effectively with cholesterol for
the substrate binding site on P450scc.
To determine the rate of metabolism of 7DHP by 3bHSD, we
partially purified the type 1 enzyme from the human placenta.
This enabled the activity of 3bHSD to be measured using 7DHP
as substrate from the rate of NAD
+ reduction. Specificity of the
reaction for 3bHSD was demonstrated by the complete inhibition
of NAD
+ reduction by 8 mM cyanoketone (like trilostane, a
3bHSD inhibitor [35,36]). Km values for pregnenolone and 7DHP
were 9.1 mM and 29.3 mM, respectively, while Vmax values were
0.34 mmol/min/mg protein and 0.44 mmol/min/mg protein,
respectively. Thus the catalytic efficiency of 3bHSD for 7DHP
(Vm/Km) is 40% of that for pregnenolone.
3. Biological activity of 7DHP, pregnenolone and 20-
oxopregnacalciferol (pD3) in skin cells
Having documented that the adrenal gland can transform
7DHC to 7DHP, we tested the biological activity of 7DHP, pD3
(vitamin D3-like product of UVB-mediated photoconversion of
7DHP [37]) and pregnenolone as a control, in cultured normal
and malignant skin cells (Figs. 11, 12). Specifically, the above
compounds inhibited in a dose-dependent fashion proliferation of
epidermal HaCaT keratinocytes and immortalized normal
epidermal melanocytes (PIG1; pigmented and nonpigmented
cultures)(Fig. 11). There was no significant difference between
the effects of 7DHP and pregnenolone, however, pD3 was less
potent than the above compounds. Furthermore, 7DHP, preg-
nenolone, pD3 and 1,25(OH)2D3 inhibited NFkB activity in
HaCaT keratinocyes, with 7DHP being the most efficient
inhibitor, which again was significantly more potent than pD3
(Fig. 11B). Next we tested their anti-cancer activity against
hamster AbC1 and human SKMEL-188 melanoma cells. Here all
of the three compounds showed similar capacity to inhibit growth
of melanoma cells in soft agar and the effect was already significant
at doses as low as 0.1 nM (Fig. 12). Thus, products of P450scc
mediated metabolism such as 7DHP and pregnenolone are
Figure 5. Metabolism of 7DHC by adrenal glands in the presence of DL-aminoglutethimide (AGT), trilostane, forscolin and D7-
reductaseinhibitors.A. For ratadrenalstransformation of7DHC(S) to7DHP(3)was dramatically inhibitedbyAGT(red)comparedtothe incubation
with 7DHC alone (blue), while accumulation of 22(OH)7DHC (1), 20,22(OH)27DHC (2) and 7DHP (3) was enhanced by trilostane (green). Control
incubations performed with boiled adrenal fragments are shown in the inset. Incubations were carried out for 18 h. B. For pig adrenals AGT also
inhibited 7DHC metabolism (red) compared to the incubation with 7DHC alone (blue), while trilostane (green) enhanced accumulation of
22(OH)7DHC (1), 20,22(OH)27DHC (2), 7DHP (3) and 17(OH)7DHP (4). Adrenal fragments were incubated for 6 h and controls (inset) were incubated
without the substrate. C. For pig adrenals0.1 mM forscolin (green) stimulated7DHC metabolism. The labeling and the experimental conditionsare the
same as in B. D. Fragments of pig adrenal glands were incubated with increasing doses of 7DHC in the presence (T+) or absence (T2) of 0.1 mM
trilostane. The chromatograms were processed as described above. Trilostane (T) enhanced accumulation of 22(OH)7DHC (1), 20,22(OH)27DHC (2),
7DHP (3) and17(OH)7DHP(4) as a functionof 7DHC concentration. E.Fragments of rat adrenalglands were incubated with 7DHC (0.5 mM) in presence
of AY-9944 or BM15.766 (10 mM or 100 mM) and analyzed by RP-HPLC (see A for peak identification). The chromatograms were processed using
ACDLabs software and relative areas for peaks identified above were calculated. D7-reductase inhibitors enhanced production of 7DHC metabolites.
doi:10.1371/journal.pone.0004309.g005
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PLoS ONE | www.plosone.org 7 February 2009 | Volume 4 | Issue 2 | e4309Figure 6. Time-dependent metabolism of 7DHP is modified by trilostane (T). Fragments of the pig adrenal glands were incubated with
7DHP (S; 0.5 mM) in the absence (A) or presence (B) of trilostane (0.1 mM) and analyzed by RP-HPLC. Boiled adrenal fragments were used as a
negative control (blue). The major products of 7DHP metabolism affected by trilostane are marked by numbers. Time-dependent changes in the
relative concentration of the identified products in presence (T+) or absence (T-) of trilostane were calculated using ACDLabs software and are
presented in C.
doi:10.1371/journal.pone.0004309.g006
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origin. This raises the possibility that they may act in auto or
paracrine fashion after local production [10,19]. Interestingly,
pD3 (vitamin D3-like photoderivative of 7DHP) also demonstrates
a potent anti-proliferative potential, but is less active than its
precursor 7-DHP. Nevertheless, this biological activity has
significant implications taking into consideration that pregnacalci-
ferol and 20-oxopregnacalciferol have no or very low calcemic
activity, respectively [37,38]. Furthermore, since the skin is
exposed to solar radiation during the daytime, 7DHP (whether
delivered by the circulation or produced locally) will be converted
to 20-oxopregnacalciferol after absorption of UVB photons.
Therefore, we tested whether the mammalian skin (a major site
of 7DHC accumulation in the body) has the potential to transform
7DHC to 7DHP and further metabolize it in a similar manner to
the adrenal gland.
Figure 7. Trilostane (T) inhibits and modifies 7DHP (S) metabolism by rat adrenal glands. A. Fragments of rat adrenal glands were
incubated with 7DHP (0.5 mM) in the absence (pink) or presence (gray) of trilostane (0.1 mM) and samples analyzed by RP-HPLC. Boiled adrenal
fragments (green) or incubations without the substrate (blue) were used as negative controls. B. The relative concentrations of the identified
products affected by trilostane (T). The insert shows inhibition of 7DHP consumption by trilostane. Control marked by blue represents or incubations
without the substrate.
doi:10.1371/journal.pone.0004309.g007
Metabolism of 7-DHC
PLoS ONE | www.plosone.org 9 February 2009 | Volume 4 | Issue 2 | e4309Figure 8. LC/MS identification of the products of 7DHP metabolism by pig adrenals. Collected fraction from RT-HPLC experiment were
analyzed using the Bruker Esquire-LC/MS Spectrometer as described in Materials and Methods. Numbers correspond to the products identified in
Figs 6 and 7.
doi:10.1371/journal.pone.0004309.g008
Metabolism of 7-DHC
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Previously we have reported the expression of P450scc and its
electrontransferpartnersinthe skinand demonstratedthe capability
of skin mitochondria and intact melanoma cells to transform
cholesterol to pregnenolone [10]. Since the activity of P450scc is low
in skin [10] (too low to detect ex-vivo production of 7DHP by above
methods), we isolated mitochondria from rat skin to test 7DHC
metabolism. Fig. 13A clearly shows that 7DHC is metabolized to
7DHP, based on the identical RT of the product to authentic
standard and the expected 5,7-diene UV spectrum. We were also
ableto show that the skinextracts could metabolize 7DHP to a more
polar 5,7-diene product with RT of 11.9 min (Fig. 13B). This
indicates that the skin has a potential to transform 7DHC to 7 DHP
and then further modify the 7DHP (most likely by hydroxylation).
Because of the noisy background in the chromatogram for the above
experiment using skin mitochondria, we isolated a skin microsomal
fraction and incubated it with 7DHP, then analyzed the products on
anLC-MSQP8000a asdetailed inMaterials andMethods.Wehave
found that skin microsomes metabolized 7DHP to two new products
with UVlmax 280 indicating modification oftheA and B ringswith
likely generation of 4,6-dienes (not shown). Although the structure of
these compounds and enzymes involved in their synthesis remain to
be identified, we can clearly conclude that the skin has the capability
to produce 7DHP and to metabolize it with preservation of the 5,7-
dienal structure or at least its degree of unsaturation. Such a
capability supports an auto or paracrine role for 7DHP itself or of its
metabolites including pregnacalciferols generated photolytically.
5. Conclusions and Perspective
Following our previous demonstration that mammalian P450scc
in an in vitro reconstituted system can cleave the side chain of
7DHC to produce 7DHP [10], we now demonstrate that adrenal
glands from different mammalian species maintained ex vivo can
efficiently transform 7DHC to 7DHP in a process that is
Figure 9. Proposed pathways for the in vivo metabolism of 7DHC in the mammalian adrenal gland.
doi:10.1371/journal.pone.0004309.g009
Metabolism of 7-DHC
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22(OH)7DHC and 20,22(OH)27DHC as intermediates. Further-
more, 7DHP can be metabolized further along the D
4 and D
5
steroidogenic pathways with production of 7-dehydroprogesterone
and 17(OH)7DHP as intermediates, which depends on the
mammalian species. Thus, normal adrenal glands can produce
steroidal 5,7 and 4,7-dienes from 7DHC via known steroidogenic
enzymes, a capability previously thought to be restricted to
pathological conditions (SLOS secondary to genetic inactivation of
7D reductase [17,18,32,33]) or to mare’s gonads under physio-
logical conditions for the synthesis of equilin (delta-7-estrone) [39].
The skin is known to express functional steroidogenic enzymes
and skin cells or hair follicles can produce steroidal intermediates,
corticosterone or cortisol [10,19,40–44]. Therefore, although the
activity of this pathway is comparatively low [10], it is not
surprising that skin mitochondria can produce 7DHP, while skin
extracts or isolated microsomes can, further metabolize it to
steroidal 5,7-dienes or to products with a modified B ring
structure. Such a capability is highly significant because the skin
is an important repository of 7DHC (making it readily available to
cutaneous P450scc), and because its exposure to solar radiation
can cause the unsaturated B ring of 7-DHP and its hydroxyder-
ivatives to break generating novel vitamin D-like compounds
without the side chain [45,46], in a process similar to production
of vitamin D3 [21]. This significance is further enhanced by our
demonstration that pregnenolone, 7DHP and pD3 display
different biological activities on skin cells. Thus, the described
above new novel steroido/secosteroidogenic pathway could in the
skin potentially operate in an intra-, auto- or paracrine mode.
In summary, we define a novel steroidogenic pathway:
7DHCR22(OH)7DHCR20,22(OH)27DHCR7DHP, with a po-
tential for further 7DHP metabolism mediated by other
steroidogenic enzymes including 3bHSD or CYP17(depending
on mammalian species). The potential flux through the pathway
and biological activity of its products depends on the organ
(adrenals vs skin), and of which 5,7-dienal intermediates can be
converted to active secosteroids after exposure to solar radiation.
Materials and Methods
Tissue collection and preparation
Adrenal glands were obtained from 2–4 months old male and
female rats (Wistar or Sprague-Dawley), after killing under
anesthesia as described previously [10,47]. In addition, adrenal
glands were obtained from pigs (York-Land, 3 months old males
and females), rabbits (New Zeland, 3–5 months old males and
females) and dogs (Walker hounds, 6 months old males). The
Institutional Animal Care and Use Committee at UTHSC
approved the original protocols; similarly the experiments were
approved by the Belarus University Animal Care and Use
Committee. All animal experimentation described was conducted
in accord with accepted standards of human animal care, as
outlined in the ethical guidelines.
Metabolism of steroids by adrenal glands
Fresh adrenal glands were dissected from connective tissue, cut
with scissors into small fragments and suspended in buffer (pH 7.4)
containing 33 mM Tris aminomethane, 110 mM NaCl, 5 mM
KCl, 2.5 mM CaCl2, 1 mM MgSO4, 1 mM KH2PO4 and 2 mg/
ml glucose (3). Prior to assay, adrenal fragments were pre-
incubated in 0.5 ml of the above buffer (50–100 mg of adrenal
tissue per ml) in a water bath for 5 min at 37uC with continuous
gentle shaking. Reactions were started by adding isocitrate (final
concentration 5 mM) followed by addition of 7DHC or 7DHP
(final concentration of 0.5 mM) and tubes incubated at 37uC for
4–6 h or as indicated. Five or 10 mM stock solutions of 7-
dehydrocholesterol (cholesta-5,7-dien-3b-ol; 7DHC) or 7-dehy-
dropregnenolone (3b-hydroxypregna-5,7-dien-20-one; 7DHP)
were prepared in 45% 2-hydroxypropyl-b-cyclodextrin immedi-
ately before use. 7DHC was purchased from Sigma Chemical Co.
(St. Louis, MO), while 7DHP was synthesized and purified as
described [1]. The initial testing for time- and dose- dependent
effects showed that the above tissue and substrate concentrations,
and time of incubation were optimal for metabolism of 7DHC and
7DHP (not shown). In control experiments, either 7DHC or
7DHP were omitted from the incubation mixture or fragments of
adrenal glands were boiled for 5 min before addition of the
substrates. The reactions were stopped by placing the tubes on ice
and steroids were extracted twice with methylene chloride and
Figure 10. Stimulation of 7DHC transfer between membranes
and the inhibition of the side chain cleavage of [cholesterol by
7DHC. A. To study 7DHC transfer between membranes by N-62 StAR
protein cholesterol or 7DHC was placed in donor vesicles at a molar
ratio to phospholipid of 0.2. The transfer of the sterol to acceptor
vesicles at 35uC was measured in the presence or absence of 5 mM N-62
StAR protein. B. Inhibition of the side chain cleavage of [4-
14C]choles-
terol by 7DHC was determined with substrate and cytochrome P450scc
incorporated into phospholipid (PL) vesicles prepared from dioleoyl
phosphatidylcholine containing ardiolipin. As indicated in the figure,
7DHC was included in the membrane at a molar ratio to phospholipid
of 0.2. The rate of side chain cleavage of [4-
14C]cholesterol was
determined from the amount of [4-
14C]pregnenolone formed.
doi:10.1371/journal.pone.0004309.g010
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RVC 2–18 (Christ, Germany). The residues were re-dissolved in
methanol for further analysis.
Reverse phase-liquid chromatography (RP-HPLC) and
mass spectrometry analyses
Three different HPLC and mass spectrometry systems were used
due to the project being carried out at several separate institutions.
The independent analyses in the different laboratories confirmed the
major findings of this study. First, RP-HPLC was performed using a
dual pump chromatography system (Waters Ass. Inst) equipped with
a Waters Atlantis dC18 column (10064.6 mm, 5 mmp a r t i c l es i z e )
using a mobile phase of methanol in H2O, as described previously
[48]. In most experiments, a gradient of methanol in water (55%–
97%) was used for elution at a flow rate 1 mL/min (42 min),
followed by a wash with 97% methanol (8 min), unless specified in
the figures. Fractions were monitored with a photodiode array or
dual wave-length detector. Alternatively, samples were resolved by a
Waters HPLC system as described above, but the separation was
accelerated by running the gradient (55%–97%) for 20 minutes
followed by the 97% methanol wash for 7 min. Fractions were
collected every 30 seconds and analyzed with a Bruker Esquire-LC/
MS Spectrometer by direct injection into the MS module [45].
Mass spectra were also recorded using a Bruker Esquire-LC/MS
Spectrometer equipped with an electrospray ionization (ESI) source,
aW a t e r sA t l a n t i sd C 1 8c o l u m n( 1 0 0 64.6 mm, 5 mmp a r t i c l es i z e ) ,
using a mobile phase of 85% methanol and 15% water at a flow rate
of 0.25 mL/min (15 min), as described previously [45].
Some samples were analyzed by HPLC on an LC–MS
QP8000a (Shimadzu, Japan) equipped with a Restec Allure C18
column (15064.6 mm; 5 mm particle size; 60 A ˚ pore size), UV/
VIS photodiode array detector (SPD-M10Avp) and single
quadrupole mass-spectrometric detectors [47,49]. The LC work-
station CLASS-8000 software was used for system control and
data acquisition (Shimadzu). The mass spectrometer was operated
in the atmospheric pressure chemical ionization (APCI) mode;
positive ion mode was used with nitrogen as the nebulizing gas.
The MS parameters were as follows: nebulizer gas flow rate 2.5
L?min
21; probe high voltage 4.5 kV; probe temperature 480uC;
curved desolvation line heater temperature 285uC. Analyses were
carried out in the scan mode from m/z 280–450. For minced
adrenal glands and skin microsome incubations, elution of samples
was carried out using a linear gradient at a flow rate of
0.5 mL?min
21 and temperature of 40uC, from 65 to 70% of
methanol and 0.1%(v/v) acetic acid (0–15 min); from 70 to 85%
of methanol and 0.1%(v/v) acetic acid (15–30 min); from 85 to
100% of methanol and 0.1%(v/v) acetic acid (30–35 min);
followed by isocratic elution with 100% of methanol and
0.1%(v/v) acetic acid from 35 to 45 min. The elution for samples
of skin mitochondria was carried out isocratically from 0–12 min
(80% methanol and 0.1% acetic acid, followed by a linear gradient
from 80–100% methanol and 0.1% acetic acid (12–20 min), then
isocratically using 10% methanol and 0.1% acetic acid from 20–
60 min. For skin extracts the mobile phase consisted of 75%
methanol and 0.1% acetic acid.
Metabolism of 7DHC and 7DHP by rat skin
Skin extracts, microsomes and mitochondria were prepared
from the shaved full thickness dorsal skin, after removal of the
subcutaneous fatty tissue. Skin was minced thoroughly with
surgical scissors and a tissue grinder, placed in isolation buffer
comprising 2 mM HEPES (pH 7.4), 70 mM sucrose, 220 mM D-
mannitol and 2 mM EDTA then homogenized using a glass
pestle. For the isolation of mitochondria and microsomes the
homogenate was centrifuged at 576 g for 10 min at 4uC and the
resulting supernatant was removed and centrifuged again at
10,000 g for 20 min at 4uC to get a mitochondrial fraction [40].
The supernatant was used for the isolation of microsomes by
centrifuging at 105,000 g for 1 h at 4uC. The mitochondrial pellet
was re-suspended in isolation buffer and the centrifugation was
repeated twice under the same conditions [10,49]. The micro-
somal pellet was re-suspended in 10 mM Tris-HCl (pH 7,4) and
the centrifugation was repeated at 105,000 g for 1 h at 4uC. The
washed microsomal fraction was re-suspended in 10 mM Tris-
HCl (pH 7,4) and immediately used for the enzyme assay [50]. To
study 7DHP metabolism in skin homogenate, the homogenate was
centrifuged at 1200 g at 4uC for 10 min and the supernatant was
collected and used for further experiments.
To test for metabolism of 7DHC, the washed mitochondrial
fraction was re-suspended in HEPES-buffered medium (0,25 M
sucrose, 50 mM HEPES, 20 mM KCl, 5 mM MgSO4, 0.2 mM
EDTA, (pH 7.4)) and incubated with 0.5 mM 7DHC and 5 mM
isocitrate at 37uC for 4 h. The control comprised mitochondria
boiled prior to the incubation. Reactions were stopped by adding
methylene chloride, and samples extracted twice with this solvent.
The methylene chloride layers were combined and dried in a
rotational vacuum concentrator RVC 2–18 (Christ, Germany).
The residues were re-dissolved in methanol and subjected to
HPLC analysis on an LC–MS QP8000a (Shimadzu, Japan). To
study 7DHP metabolism by skin homogenate, the 1200 g
supernatants were pre-incubated for 10 min at 37uC with
20 mM 7DHP (added form a methanol stock) in 0.5 ml of
10 mM Tris-HCl, (pH 7.4). Reactions were started by adding
5 mM isocitrate and 0.5 mM NADPH and samples incubated at
37uC for 90 min. Reactions were then stopped and analyzed by
HPLC as above. To study microsomal metabolism the skin
microsomes were pre-incubated in 10 mM Tris-HCl (pH 7.4) with
0.5 mM 7DHP for 10 min at 37uC with continuous gentle
shaking. Reactions were initiated by adding 1 mM NADPH and
carried out at 37uC for 2 h.
Interaction of 7DHC and 7DHP with purified
steroidogenic enzymes
Transfer of 7DHC and cholesterol from acidic dioleoyl
phosphatidylcholine donor vesicles containing cardiolipin, to
neutral dioleoyl phosphatidylcholine acceptor vesicles, was mea-
sured in the presence and absence of N-62 StAR protein (a gift
from Walter Miller, University of California, San Francisco). The
incubations and subsequent separation of acidic and neutral
vesicles by DEAE Sepharose chromatography, were done as
described before [51].
Figure 11. The effect of 7DHP, pregnacholecalciferol (pD3) and pregnenolone on normal immortalized epidermal HaCaT
keratinocytes and PIG1 melanocytes. A and B. Inhibition of HaCaT cell proliferation as measured by [
3H]-thymidine incorporation (A) and MTT
(B) assays after 48 h and 72 h of treatment, respectively. C. Inhibition of NFkB activity in HaCaT keratinocytes 24 h after transfection with luciferase
construct NFkB-Luc. The cells were treated for 24 h with 100 nM vitamin D3 (vD3), 1,25(OH)2D3, 7DHP, pD3, pregnenolone or ethanol vehicle
(control) and luciferase activity was measured in cell extracts. D and E. Inhibition of cell growth as measured by sulforhodamine b assay (protein
content) after 72 h of treatment of non-pigmented (D) and pigmented (E) PIG1 human melanocytes. Inserts show the color of representative cell
pellets. Significant differences versus ethanol-treated control cells were defined as *p,0.05, **p,0.01, ***p,0.001.
doi:10.1371/journal.pone.0004309.g011
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before [52]. The side chain cleavage activity of P450scc in
phospholipid vesicles was determined using [4-
14C]cholesterol as
substrate. Vesicles were prepared from dioleoyl phosphatidylcho-
line and cardiolipin in the molar ratio of 85:15, plus tracer [4–
14C]cholesterol, using a bath sonicator as before [51]. When
Figure 12. 7DHP, 20-oxopregnacalciferol (pD3) and pregnenolone inhibit growth of melanoma cells in soft agar. A: hamster AbC1
melanoma; B: human SKMEL-188 melanoma; C: visualization of SKMEL-188 colonies by MTT reagent. Decreased number and size of colonies was
observed in both cell lines. Significant differences versus ethanol-treated cells were defined as *p,0.05, **p,0.01, ***p,0.001.
doi:10.1371/journal.pone.0004309.g012
Figure 13. Metabolism of 7DHC and 7DHP by rat skin. A. To study the skin capability to transform 7DHC to 7DHP isolated mitochondria were
incubated with 7DHC (0.5 mM) in the presence (experimental) or absence (control) of isocitrate and NADPH. 7DHP: product with the same retention
time and UV spectra (inset) as 7DHP standard. B. Incubation of crude skin extract with 7DHP substrate (RT 16.7 min) in the presence of isocitrate and
NADPH (experimental) resulted in appearance of a 5,7-diene product (N) with RT 11.9 min, which was absent in control reaction mixture (isocitrate
and NADPH were not added) (control).
doi:10.1371/journal.pone.0004309.g013
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phospholipid of 0.2. Incubations with P450scc were carried out for
2 min at 37uC, the reaction stopped and steroids extracted with
dichloromethane as described previously [51]. Radiolabelled
cholesterol and pregnenolone were separated by thin-layer
chromatography on silica gel G with three developments in
hexane:acetone (7:3, v/v). The areas of silica gel corresponding to
cholesterol and pregnenolone were removed separately and the
associated radioactivity determined by scintillation counting.
3bHSD was partially purified from 114 g human placenta by
extraction of a combined mitochondrial and microsomal fraction
with 0.6% sodium cholate, followed by chromatography on DEAE
Sepharose as described by Thomas et al [53]. Activity was assayed
at 35uC from NAD
+ reduction monitored at 340 nm in an
incubation mixture comprising 3bHSD (2.25 mg/mL), 20 mM
potassium phosphate pH 7.5, 0.1 mM EDTA, 0.1 mM dithio-
threitol 0.1 mM NAD
+, 0.4% Emulgen 913 and 20% glycerol.
Substrates (5–30 mM) were added in ethanol to a final ethanol
concentration of 2%.
Cell culture experiments
Immortalized human keratinocytes (HaCaT) were cultured in
Dulbecco’s Modified Eagle Medium supplemented with glucose,
L-glutamine, pyridoxine hydrochloride (Cell Grow), 5% foetal
bovine serum (FBS) and 1% penicillin/streptomycin/amphoteri-
cin antibiotic solution (Sigma) [54]. The melanoma cell lines,
human SK Mel 188 and hamster AbC1, were grown in F10 media
(Gibco) supplemented with 5% FBS [55]. Human immortalized
melanocytes PIG1, including a pigmented line (gift of Dr LePoole
[56]) and an amelanotic variant (that lost the ability to produce
pigment during subculturing [57]), were grown in medium 254
supplemented with 5%HMGS for melanocytes from Cascade
Biologics.
To study DNA synthesis, HaCaT keratinocytes were plated in
24-well plates at 50,000 cells/well. After overnight incubation,
pD3, 7DHP and pregnenolone, initially dissolved in ethanol
before dilution with DMEM medium containing 5% charcoal-
treated serum, were added to the culture medium at the
concentrations listed (see Results). After 44 h, [
3H]-thymidine
(specific activity 88.0 Ci/mmol; Amersham Biosciences, Picat-
away, NY, USA) was added to a final concentration of 1 mCi/mL
medium. After 4 h, media were discarded, cells washed with cold
PBS and incubated in 10% TCA for 30 min. Cells were washed
again with PBS and incubated with 1 N NaOH (100 mL/well) for
30 min at 30uC. The extracts were collected, scintillation cocktail
added and
3H-radioactivity was measured with a beta counter
(Direct Beta-Counter Matrix 9600; Packard), as described
previously [12,55].
MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide] viability tests were performed as previously described [54].
HaCaT cells were seeded at 5,000 per well in 96 well plates. After
12 h media were changed and pD3, 7DHP and pregnenolone were
added to achieve test concentrations 10
28–10
210 M. After 68 h of
incubation, MTT assays were performed as described previously
with absorbance measured at 570 nm [26,54].
To measure cell growth an additional sulphorhodamine b (SRB)
assay, which estimates the protein content of cells, was performed
[58]. Briefly, immortalized human epidermal melanocytes (line
PIG1) were seeded at 10,000 cells per well in 96 well-plates with
melanocyte growth medium [40]. After 12 h the medium was
changed to medium containing pD3, 7DHP and pregnenolone.
After 71 h of incubation, 50% acetic acid was added to a final
concentration of 20%, cells stained with SRB (Sigma), washed
with 1% acetic acid, dried, dissolved in Tris-HCl and the
absorbance measured at 565 nm [58].
The tumorogenicity of SKMEL-188 and AbC1 melanoma cells
was determined by assaying their ability to form colonies in soft
agar. Cells growing in monolayer culture were trypsinized and re-
suspended (1,000 cells/well) in 0.25 ml medium containing 0.4%
agarose and 5% charcoal-stripped serum (HyClone). Cell
suspensions were added to a 0.8% agar layer in 24 well plates.
pD3, 7DHP and pregnenolone were added from ethanol stocks to
final concentrations ranging from 0.1 nM to 100 nM. An ethanol
solvent control was included in the assay. Soft agar colonies were
scored and stained after two weeks, with 0.5 mg/ml MTT reagent
(Promega). Colonies were counted under the microscope and the
number of units was calculated from the number of colonies
formed divided by the number of cells seeded 6100.
To measure the NFkB activity, HaCaT keratinocytes were
transfected with the NFkB-Luc construct using Lipofectamine Plus
(Invitrogen, Carlsbad, CA) as described previously [59]. Twenty
four hours after transfection the media were changed and pD3,
7DHP, pregnenolone or ethanol (vehicle control) were added and
cells incubated for 24 h. The firefly luciferase and Renilla
luciferase signals were recorded with a TD-20/20 luminometer
(Turner Designs, Sunnyvale, CA) and and activities calculated as
described previously [57,59].
Statistical analysis was performed with GraphPad Prism
Version 4.0 (GraphPad Software Inc., San Diego, CA, USA)
using t test. Differences were considered significant when p,0.05.
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